DDInter1544 DDInter1615
Prucalopride is a dihydrobenzofurancarboxamide derivative from the benzofurane family that selectively stimulates 5-HT4 receptors and thus, it presents enterokinetic properties. The high selectivity of prucalopride allowed further development as it prevented the cardiac adverse reactions observed due to non-target effects of precedent therapies. Prucalopride was developed by Shire Development LLC and approved for use in Europe in 2009, in Canada on December 7, 2011 and by the FDA on December 17, 2018.
Rolapitant is a potent, highly selective, long-acting Neurokinin-1 (NK-1) receptor antagonist approved for the prevention of delayed chemotherapy-induced nausea and vomiting (CINV) in adults. Delayed-phase CINV typically occurs >24 hours after chemotherapy treatment and is principally mediated by Neurokinin-1 and its ligand Substance P, which is released in the gut following chemotherapy administration. Neurokinin-1 is also known as Tachykinin Receptor 1 (TACR1), Neurokinin 1 Receptor (NK1R), and Substance P Receptor (SPR). By blocking Substance P from interacting with NK-1 receptors in the gut and the central nervous system, rolapitant prevents late-phase CINV. Unlike other available NK-1 receptor antagonists, rolapitant is not an inhibitor of Cytochrome P450 enzyme CYP3A4 and has a long elimination half-life, allowing a single dose to prevent both acute and late-phase CINV during the first 120 hours post-chemotherapy.
Rolapitant {u} may cause a minor interaction that can limit clinical effects when taken with {v} Tolterodine
Rolapitant {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dextromethorphan
Rolapitant {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Larotrectinib
Rolapitant {u} may lead to a major life threatening interaction when taken with {v} Enzalutamide
Rolapitant {u} may lead to a major life threatening interaction when taken with {v} Betrixaban
Rolapitant may cause a minor interaction that can limit clinical effects when taken with Tolterodine
Rolapitant may cause a moderate interaction that could exacerbate diseases when taken with Dextromethorphan
Rolapitant may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib
Rolapitant may lead to a major life threatening interaction when taken with Enzalutamide
Rolapitant may lead to a major life threatening interaction when taken with Betrixaban